Infusion reactions and their management.
Infliximab therapy should be optimized to minimize immunogenicity, to prevent infusion reactions, and to maintain clinical response. Based on best available evidence, strategies include minimizing the formation of ATI by administering infliximab as a multidose induction therapy followed by scheduled maintenance regiment, the use of concurrent immunomodulators, and possibly premedicating with steroids. Infusion reaction are common and they can be managed using specific protocols outlined in this article.
Mayer
Lloyd
L
Division of Gastroenterology and Clinical Immunology, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1089, New York, NY 10029, USA. lloyd.mayer@mssm.edu
Young
Yuki
Y
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects* / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects* / Q000187:drug effects / Q000276:immunology; D005765:Gastrointestinal Agents / Q000008:administration & dosage* / Q000009:adverse effects* / Q000276:immunology; D006801:Humans; D007107:Immune System / Q000187:drug effects; D000069285:Infliximab; D007262:Infusions, Intravenous / Q000009:adverse effects; D012720:Severity of Illness Index
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab